All lobbying filings

AVENUE SOLUTIONS

Lobbying for GENENTECH USA, INC. · Biotechnology

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $50,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 3

HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 2

Health Issues

Issues related to 340b drug pricing program; Expiring healthcare extenders

Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.